<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_Worldshaper-Wuhan_Results skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:Worldshaper-Wuhan/Results</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="wrapper" id="wrapper"><HEADER class="top-menu"><NAV class="navbar background-transparent position-fixed fixed-white-background static-nav no-animation"><DIV class="container"><DIV class="row"><UL class="nav navbar-nav navbar-left navlinks-outer collapse navbar-collapse white-color no-hvr"><LI class="nav-tab"><A href="https://2018.igem.org/Team:Worldshaper-Wuhan" class="font-style-1 nav-item scroll">HOME</A></LI><LI class="nav-tab"><A href="https://2018.igem.org/Team:Worldshaper-Wuhan/Background" class="font-style-1 nav-item scroll">BACKGROUND</A> </LI><LI class="nav-tab nar-dropdown"><A class="font-style-1 nav-item scroll">PROJECT</A><DIV class="dropdown-content"><A href="https://2018.igem.org/Team:Worldshaper-Wuhan/Solution">SOLUTION</A><A href="https://2018.igem.org/Team:Worldshaper-Wuhan/Results">RESULTS</A><A href="https://2018.igem.org/Team:Worldshaper-Wuhan/Model">MODEL</A><A href="https://2018.igem.org/Team:Worldshaper-Wuhan/Procedure">PROCEDURE</A><A href="https://2018.igem.org/Team:Worldshaper-Wuhan/Notebook">NOTEBOOK</A></DIV></LI><LI class="nav-tab"><A href="https://2018.igem.org/Team:Worldshaper-Wuhan/InterLab" class="font-style-1 nav-item scroll">INTERLAB</A></LI></UL><UL class="nav navbar-nav navbar-right navlinks-outer collapse navbar-collapse white-color no-hvr"><LI class="nav-tab nar-dropdown"><A class="font-style-1 nav-item scroll">HUMAN PRACTICE</A><DIV class="dropdown-content"><A href="https://2018.igem.org/Team:Worldshaper-Wuhan/Human_Practices">SILVER</A><A href="https://2018.igem.org/Team:Worldshaper-Wuhan/HP/Gold_Integrated">GOLD</A><A href="https://2018.igem.org/Team:Worldshaper-Wuhan/Public_Engagement">PUBLIC ENGAGEMENT</A><A href="https://2018.igem.org/Team:Worldshaper-Wuhan/Collaborations">COLLABORATIONS</A></DIV></LI><LI class="nav-tab nar-dropdown"><A class="font-style-1 nav-item scroll">PARTS</A><DIV class="dropdown-content"><A href="https://2018.igem.org/Team:Worldshaper-Wuhan/Basic_Part">BASIC</A><A href="https://2018.igem.org/Team:Worldshaper-Wuhan/Improve">IMPROVE</A></DIV></LI><LI class="nav-tab"><A href="https://2018.igem.org/Team:Worldshaper-Wuhan/Safety" class="font-style-1 nav-item scroll">SAFETY</A></LI><LI class="nav-tab"><A href="https://2018.igem.org/Team:Worldshaper-Wuhan/Attributions" class="font-style-1 nav-item scroll">ATTRIBUTIONS</A></LI></UL></DIV></DIV></NAV></HEADER><SECTION id="home" class="main-section z-index100"><H2 class="displaynone">heading</H2><DIV id="rev_slider_2_1_wrapper" class="rev_slider_wrapper fullscreen-container paintbrush-overlay" data-alias="paintbrush-addon" data-source="gallery" style="background:transparent;padding:0;"><DIV id="rev_slider_2_1" class="rev_slider fullscreenbanner" style="display:none;" data-version="5.4.8.1"><UL><LI data-index="rs-4" data-transition="fade" data-slotamount="default" data-hideafterloop="0" data-hideslideonmobile="off" data-easein="default" data-easeout="default" data-masterspeed="300" data-rotate="0" data-saveperformance="off" data-title="Slide" data-param1="" data-param2="" data-param3="" data-param4="" data-param5="" data-param6="" data-param7="" data-param8="" data-param9="" data-param10="" data-description="" data-revaddonpaintbrush="{&quot;size&quot;:200,&quot;origsize&quot;:200,&quot;blurAmount&quot;:10,&quot;fadetime&quot;:600,&quot;image&quot;:&quot;http:\/\/igem2017.worldshaper.cn\/2018\/Wuhan\/images\/paintbrush-bg.jpg&quot;,&quot;edgefix&quot;:10,&quot;fixedges&quot;:true,&quot;style&quot;:&quot;round&quot;,&quot;blur&quot;:true,&quot;scaleblur&quot;:false,&quot;responsive&quot;:false,&quot;disappear&quot;:true,&quot;carousel&quot;:false}" data-revaddonpaintbrushedges="1"><DIV class="tp-caption   tp-resizeme" id="slide-25-layer-1" data-x="['center','center','center','center']" data-hoffset="['0','0','0','0']" data-y="['middle','middle','middle','middle']" data-voffset="['-100','-100','-100','-100']" data-fontsize="['110','90','100','70']" data-lineheight="['100','90','100','70']" data-width="['none','none','697','399']" data-height="none" data-whitespace="['nowrap','nowrap','normal','normal']" data-type="text" data-basealign="slide" data-responsive_offset="on" data-frames="[{&quot;delay&quot;:&quot;+290&quot;,&quot;split&quot;:&quot;chars&quot;,&quot;splitdelay&quot;:0.05,&quot;speed&quot;:750,&quot;frame&quot;:&quot;0&quot;,&quot;from&quot;:&quot;y:40px;sX:1.5;sY:1.5;opacity:0;fb:20px;&quot;,&quot;to&quot;:&quot;o:1;fb:0;&quot;,&quot;ease&quot;:&quot;Power4.easeOut&quot;},{&quot;delay&quot;:&quot;wait&quot;,&quot;speed&quot;:1000,&quot;frame&quot;:&quot;999&quot;,&quot;to&quot;:&quot;sX:1;sY:1;opacity:0;fb:10px;&quot;,&quot;ease&quot;:&quot;Power4.easeOut&quot;}]" data-margintop="[0,0,0,0]" data-marginright="[0,0,0,0]" data-marginbottom="[30,20,30,30]" data-marginleft="[0,0,0,0]" data-textalign="['inherit','inherit','center','center']" data-paddingtop="[0,0,0,0]" data-paddingright="[0,0,40,40]" data-paddingbottom="[0,0,0,0]" data-paddingleft="[0,0,40,40]" style="z-index: 8; white-space: nowrap; font-size: 110px; line-height: 100px; font-weight: 600; color: rgba(255, 255, 255, 1.00); display: inline-block;font-family: 'Poppins', sans-serif;letter-spacing:-5px;">RESULTS</DIV><DIV class="tp-caption   tp-resizeme" id="slide-25-layer-3" data-x="['center','center','center','center']" data-hoffset="['0','0','0','0']" data-y="['top','top','top','top']" data-voffset="['565','550','618','495']" data-fontsize="['20','20','16','12']" data-width="none" data-height="none" data-whitespace="nowrap" data-type="text" data-responsive_offset="on" data-frames="[{&quot;delay&quot;:1879.8611450195,&quot;speed&quot;:2000,&quot;frame&quot;:&quot;0&quot;,&quot;from&quot;:&quot;z:0;rX:0;rY:0;rZ:0;sX:0.9;sY:0.9;skX:0;skY:0;opacity:0;&quot;,&quot;to&quot;:&quot;o:1;&quot;,&quot;ease&quot;:&quot;Power2.easeOut&quot;},{&quot;delay&quot;:&quot;wait&quot;,&quot;speed&quot;:300,&quot;frame&quot;:&quot;999&quot;,&quot;to&quot;:&quot;opacity:0;&quot;,&quot;ease&quot;:&quot;Power3.easeInOut&quot;}]" data-textalign="['inherit','inherit','inherit','inherit']" data-paddingtop="[0,0,0,0]" data-paddingright="[0,0,0,0]" data-paddingbottom="[0,0,0,0]" data-paddingleft="[0,0,0,0]" style="z-index: 8;"><A href="#aboutus" class="scroll btn btn-green btn-rounded paint-brush-button btn-hvr-white">learn more</A></DIV></LI></UL></DIV></DIV></SECTION><SECTION id="aboutus" class="half-section"><DIV class="container-fluid"><DIV class="row"><DIV class="col-lg-6 col-md-6 col-sm-12 col-xs-12 no-padding"><DIV class="split-box text-center center-block container-padding equalheight"><DIV class="paddingtopbottom100px padding-l-r200px"><H1 class="font-style-1 text-color-grey no-margin wow fadeInUp" data-wow-delay="400ms"><SPAN class="font-style-1-u">Our</SPAN><SPAN class="brown-color"> Results </SPAN></H1><P class="top40 bottom40 font-weight-100 line-height-30px text-color-black wow fadeInUp" data-wow-delay="400ms"><U>Identification of IL7-AS expression in renal cell carcinoma by TANRIC</U></P><P class="top40 bottom40 font-weight-100 line-height-30px text-color-black wow fadeInUp" data-wow-delay="500ms">Based on evidence that IL7-AS can be induced across multiple human and mouse cell types and has been reported to regulate the expression of interleukin-6 (IL6). IL6 is emerging as a major regulator of renal cell cancer. We asked whether IL7-AS is involved in pathogenesis of renal cell carcinoma. By analyzing data from TANRIC (http://ibl.mdanderson.org/tanric/_design/basic/query.html), we collected the expression data of IL7-AS in 64 normal tissues and 432 kidney renal clear cell carcinoma tissues. IL7-AS was expressed at higher levels in kidney renal clear cell carcinoma (KIRC) than in normal kidney (Fig. 1).
                                </P><P class="font-size-15px top10 bottom0 font-weight-100 line-height-30px text-color-black wow fadeInUp" data-wow-delay="400ms">
                                Fig. 1 IL7-AS was expressed at higher levels in kidney renal clear cell carcinoma than in normal kidney by TANRIC.</P><P class="top40 bottom40 font-weight-100 line-height-30px text-color-black wow fadeInUp" data-wow-delay="400ms"><U>Identification of IL7-AS expression in kidney cancer cell lines</U></P><P class="top40 bottom40 font-weight-100 line-height-30px text-color-black wow fadeInUp" data-wow-delay="500ms">
                                The 769-P and 786-O cell lines are derived from primary clear cell adenocarcinoma. The 293T cell line is originally derived from human embryonic kidney. We examined the expression levels of IL7-AS in 769-P, 786-O and HEK-293T cell lines. IL7-AS expression was markedly higher in 786-O and 769-P cells than in HEK-293T cells (Fig. 2). We also observed that up-regulated IL7-AS expression was correlated with IL6 expressions in these cell lines (Fig. 2).
                                </P><P class="font-size-15px top10 bottom0 font-weight-100 line-height-30px text-color-black wow fadeInUp" data-wow-delay="400ms">
                                Fig. 2 Compared to HEK-293T, IL7-AS was highly expressed in 786-O and 769-P cells as shown by real-time PCR</P><P class="top40 bottom40 font-weight-100 line-height-30px text-color-black wow fadeInUp" data-wow-delay="400ms"><U>IL7-AS promotes kidney cancer cell migration</U></P><P class="top40 bottom40 font-weight-100 line-height-30px text-color-black wow fadeInUp" data-wow-delay="500ms">
                                Cell migration is a central process in the development and maintenance of tumor. We cloned the full length of IL7-AS, two truncated sequences of IL7-AS (IL7-AS-S1 and IL7-AS-S2) into PCDNA3.1 (Fig. 3) and transfected these plasmids to 786-O cells. Through in vitro scratch wound healing assay, overexpression of IL7-AS promoted cell migration of 786-O cells (Fig. 4 and 5). In order to determine which domain is essential for the migration of IL7-AS, we cloned two truncated sequences of IL7-AS (IL7-AS-S1 and IL7-AS-S2). Overexpression of IL7-AS-S1 or IL7-AS-S2 increased the migration of 786-O cells (Fig. 4 and 5). These results suggested that IL7-AS-S1 and IL7-AS-S2 contain key structural domains. IL7-AS may play an important role in migration of renal cell carcinoma.
                                </P><P class="font-size-15px top10 bottom0 font-weight-100 line-height-30px text-color-black wow fadeInUp" data-wow-delay="400ms">
                                Fig. 3 Scheme of three IL7-AS isoforms on human chromosome 8</P><P class="font-size-15px top10 bottom0 font-weight-100 line-height-30px text-color-black wow fadeInUp" data-wow-delay="400ms">
                                Fig. 4 Overexpression of IL7-AS-S2, IL7-AS-S1 and IL7-AS promotes 786-O cells migration. 786-O cells were transfected with pcDNA3.1-IL7-AS-S2, pcDNA3.1-IL7-AS-S1 or pcDNA3.1-IL7-AS for 24 h. The cells growth areas were calculated with Image J at the time points of 0, 6, 12 and 24 h. Bar=100 μm. Data represents means ± SE from 3 independent experiments. *p&lt;0.05 versus non-transfected cells.</P><P class="top40 bottom40 font-weight-100 line-height-30px text-color-black wow fadeInUp" data-wow-delay="500ms">
                                In order to investigate whether cell migration induced by IL7-AS-S2 depends on the amount of IL7-AS-S2 transfection. We transfected the different concentrations of IL7-AS-S2 (1ug, 2ug, 4ug) into 786-0 cells. Both three concentrations of IL7-AS-S2 can infect the migration of 786-0 cells (Fig. 5）.
                                </P><P class="font-size-15px top10 bottom0 font-weight-100 line-height-30px text-color-black wow fadeInUp" data-wow-delay="400ms">
                                Fig. 5 Different concentrations of IL7-AS-S2 promotes 786-O cells migration. 786-O cells were transfected with pcDNA3.1-IL7-AS-S2 (1 ug, 2 ug, 4 ug) for 24 h. The cells growth areas were calculated with Image J at the time points of 0, 6, and 12 h. Bar=100 μm. Data represents means ± SE from 3 independent experiments. *p&lt;0.05 versus non-transfected cells.</P><P class="top40 bottom40 font-weight-100 line-height-30px text-color-black wow fadeInUp" data-wow-delay="400ms"><U>IL7-AS contains a complicated secondary structure</U></P><P class="top40 bottom40 font-weight-100 line-height-30px text-color-black wow fadeInUp" data-wow-delay="500ms">
                                In silico prediction of lncRNA secondary structure is another useful method to assign putative functions to non-coding transcripts, based upon the widely held assumption that highly folded structures impart functionality through binding interactions with proteins/nucleotides. Characterization of IL7-AS, IL7-AS-S1 and IL7-AS-S2 using RNA fold minimum free energy estimations predicted a highly folded secondary structure with several hairpin loops, which imply interact with protein (Fig. 6).
                                </P><P class="top40 bottom40 font-weight-100 line-height-30px text-color-black wow fadeInUp" data-wow-delay="500ms">
                                A. IL7-AS
                                </P><P class="top40 bottom40 font-weight-100 line-height-30px text-color-black wow fadeInUp" data-wow-delay="500ms">
                                B. IL7-AS-S1
                                </P><P class="top40 bottom40 font-weight-100 line-height-30px text-color-black wow fadeInUp" data-wow-delay="500ms">
                                C. IL7-AS-S2
                                </P><P class="font-size-15px top10 bottom0 font-weight-100 line-height-30px text-color-black wow fadeInUp" data-wow-delay="400ms">
                                Fig. 6 The optimal secondary structure with a minimum free energy. The secondary structures of IL7-AS; IL7-AS-S1 and IL7-AS-S2 were predicted by the RNAfold webserver (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi). The structure is colored according to base-pairing probabilities. For unpaired regions, the color denotes the probability of being unpaired. </P><P class="top40 bottom40 font-weight-100 line-height-30px text-color-black wow fadeInUp" data-wow-delay="400ms"><U>Bioinformatic prediction of IL7-AS-S2 function</U></P><P class="top40 bottom40 font-weight-100 line-height-30px text-color-black wow fadeInUp" data-wow-delay="500ms">
                                LncRNAs perform the function through interacting with proteins. Considering IL7-AS-S2 can influence the cell migration, we want to predict proteins which can interact with IL7-AS-S2. Using the catRAPID omics algorithm (http://service.tartaglialab.com/page/catrapid_omics_group), we determined whether IL7-AS-S2 interacts with proteins. Results showed that the related RNA-binding proteins were involved in RNA-splicing/processing (CWC15, RU2A), and protein synthesis (EIF3G, SBDS) (table 1). Based on the proteins predicted, we estimated that IL7-AS-S2 may regulate RNA splicing or protein synthesis of some tumor related genes though interacting with several RNA-splicing or protein synthesis associated proteins. 
                                </P><P class="top40 bottom40 font-weight-100 line-height-30px text-color-black wow fadeInUp" data-wow-delay="500ms">
                                Table 1. Predicted proteins interacted with IL7-AS-S2
                                </P><P class="top40 bottom40 font-weight-100 line-height-30px text-color-black wow fadeInUp" data-wow-delay="400ms"><U>Conclusions and perspectives</U></P><P class="top40 bottom40 font-weight-100 line-height-30px text-color-black wow fadeInUp" data-wow-delay="500ms">
                                The results reported here demonstrate that IL7-AS may play an important role in pathogenesis of renal cell carcinoma. We found that IL7-AS was expressed at higher levels in kidney renal clear cell carcinoma than in normal kidney. Moreover, IL7-AS expression was higher in renal cell carcinoma associated cells than in human embryonic kidney cells. IL7-AS promoted the migration of renal cell carcinoma related cells. Our results for the first time to evaluate the possibility of IL7-AS in renal cell carcinoma as a novel biomarker for diagnosis and a potential target for therapy in the future.  
                                </P></DIV></DIV></DIV></DIV></DIV></SECTION></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>